BMEA
Biomea Fusion, Inc.
Price Chart
Latest Quote
$1.18
-0.02 (-1.67%)
Current Price
| Previous Close | $1.20 |
| Open | $1.23 |
| Day High | $1.26 |
| Day Low | $1.17 |
| Volume | 380,202 |
Stock Information
| Shares Outstanding | 72.30M |
| Total Debt | $1.24M |
| Cash Equivalents | $44.69M |
| Net Income | $-44.95M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $85.31M |
| EPS (TTM) | $-0.55 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $40.41M |
| Income | $-44.95M |
| Book/sh | $0.26 |
| Cash/sh | $0.62 |
| Employees | 41 |
Financial Ratios
| Quick Ratio | 4.81 |
| Current Ratio | 4.98 |
| Debt/Eq | 6.62 |
Returns & Margins
| ROA | -79.32% |
| ROE | -189.44% |
Ownership
| Insider Ownership | 7.17% |
| Institutional Ownership | 38.89% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -1.07 |
| P/B | 4.56 |
Analyst Data
| Recommendation | buy |
| Target Price | $6.83 |
Technical Indicators
| SMA20 | $1.28 |
| SMA50 | $1.50 |
| SMA200 | $1.46 |
| RSI | 33.61 |
| ATR | 0.1007 |
| Shares Float | 67.44M |
| Short Float | 24.43% |
| Short Ratio | 11.46 |
| Rel Volume | 0.39 |
Performance History
| Week | -0.84% |
| Month | -3.28% |
| Quarter | +8.26% |
| 6 Months | -13.87% |
| YTD | -11.94% |
| Year | -59.31% |
| 3 Years | -97.03% |
| 5 Years | -94.27% |
| 10 Years | -93.66% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $1.18 | 380,202 |
| 2026-06-17 | $1.20 | 707,800 |
| 2026-06-16 | $1.16 | 805,200 |
| 2026-06-15 | $1.20 | 811,400 |
| 2026-06-12 | $1.17 | 609,700 |
| 2026-06-11 | $1.19 | 775,300 |
| 2026-06-10 | $1.15 | 732,500 |
| 2026-06-09 | $1.13 | 1,018,000 |
| 2026-06-08 | $1.15 | 2,283,300 |
| 2026-06-05 | $1.27 | 1,358,000 |
| 2026-06-04 | $1.37 | 1,482,400 |
| 2026-06-03 | $1.30 | 1,299,600 |
| 2026-06-02 | $1.37 | 883,600 |
| 2026-06-01 | $1.39 | 1,083,000 |
| 2026-05-29 | $1.38 | 516,600 |
| 2026-05-28 | $1.38 | 691,300 |
| 2026-05-27 | $1.36 | 759,700 |
| 2026-05-26 | $1.41 | 1,404,200 |
| 2026-05-22 | $1.42 | 911,000 |
| 2026-05-21 | $1.37 | 777,800 |
| 2026-05-20 | $1.33 | 1,139,300 |
| 2026-05-19 | $1.22 | 1,094,100 |
| 2026-05-18 | $1.25 | 1,800,500 |
About Biomea Fusion, Inc.
Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It's lead clinical program's drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase II clinical trial of icovamenib for treating insulin-deficient type 2 diabetes; and COVALENT-212, which is in Phase II clinical trial of icovamenib for the treatment of type 2 diabetes. The company is also developing BMF-650, which is in Phase I glucagon-like peptide-131 clinical trial for the treatment of obesity. The company was incorporated in 2017 and is headquartered in San Carlos, California.
đ° Latest News
Biomea Fusion Status Update: Experts Discuss Icovamenibâs Promise Ahead of ADA 2026
MarketBeat âĸ 2026-05-05T20:20:12Z
Biomea Fusion Shares Early Type 1 Diabetes Data as COVALENT-112 Shows C-Peptide Gains with Icovamenib
MarketBeat âĸ 2026-04-28T20:31:38Z
Biomea Fusion Details Icovamenib Diabetes Milestones, Teases BMF-650 Obesity Readouts
MarketBeat âĸ 2026-03-30T21:03:24Z
Biomea Fusion Teases Q2 Phase 1 Data for Oral GLP-1 BMF-650, Advances Icovamenib in Diabetes
MarketBeat âĸ 2026-03-30T18:24:45Z
Can Biomea Fusion (NASDAQ:BMEA) Afford To Invest In Growth?
Simply Wall St. âĸ 2026-03-27T10:26:56Z
Analysts Sentiment on Biomea Fusion (BMEA) Remains Strong Amid Strong Diabetes Trial Results
Insider Monkey âĸ 2026-03-25T19:32:45Z
Biomea Fusion Details Diabetes, Obesity Pipeline at Citizens Conference, Sees Cash Runway to Q1 2027
MarketBeat âĸ 2026-03-13T07:28:17Z
Biomea Fusion Spotlights Durable Diabetes Data, Oral GLP-1 Weight-Loss Program at Oppenheimer Conf.
MarketBeat âĸ 2026-02-27T04:14:02Z
Biomea Fusion, Inc.'s (NASDAQ:BMEA) largest shareholders are retail investors with 55% ownership, institutions own 38%
Simply Wall St. âĸ 2026-01-24T13:09:12Z
Rodman & Renshaw Initiates Biomea Fusion (BMEA) at Buy with $8 Price Target
Insider Monkey âĸ 2026-01-19T13:01:51Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Total Expenses | $81,307,000 | $144,070,000 | $126,135,000 | $83,634,000 |
| Other Income Expense | $17,652,000 | - | - | - |
| Net Non Operating Interest Income Expense | $1,858,000 | $5,644,000 | $8,880,000 | $1,806,000 |
| Operating Expense | $81,307,000 | $144,070,000 | $126,135,000 | $83,634,000 |
| General And Administrative Expense | $19,328,000 | $25,985,000 | $23,589,000 | $20,921,000 |
| Total Other Finance Cost | - | - | - | - |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-61,797,000 | $-138,426,000 | $-117,255,000 | $-81,828,000 |
| Net Interest Income | $1,858,000 | $5,644,000 | $8,880,000 | $1,806,000 |
| Interest Income | $1,858,000 | $5,644,000 | $8,880,000 | $1,806,000 |
| Normalized Income | $-79,449,000 | $-138,426,000 | $-117,255,000 | $-81,828,000 |
| Net Income From Continuing And Discontinued Operation | $-61,797,000 | $-138,426,000 | $-117,255,000 | $-81,828,000 |
| Total Operating Income As Reported | $-83,512,000 | $-144,070,000 | $-126,135,000 | $-83,634,000 |
| Net Income Common Stockholders | $-61,797,000 | $-138,426,000 | $-117,255,000 | $-81,828,000 |
| Net Income | $-61,797,000 | $-138,426,000 | $-117,255,000 | $-81,828,000 |
| Net Income Including Noncontrolling Interests | $-61,797,000 | $-138,426,000 | $-117,255,000 | $-81,828,000 |
| Net Income Continuous Operations | $-61,797,000 | $-138,426,000 | $-117,255,000 | $-81,828,000 |
| Pretax Income | $-61,797,000 | $-138,426,000 | $-117,255,000 | $-81,828,000 |
| Special Income Charges | $-2,205,000 | $0 | $0 | - |
| Interest Income Non Operating | $1,858,000 | $5,644,000 | $8,880,000 | $1,806,000 |
| Operating Income | $-81,307,000 | $-144,070,000 | $-126,135,000 | $-83,634,000 |
| Per Share | ||||
| Diluted EPS | $-1.18 | $-3.83 | $-3.44 | $-2.80 |
| Basic EPS | $-1.18 | $-3.83 | $-3.44 | $-2.80 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-97,550,000 | $-142,322,000 | $-124,620,000 | $-82,943,000 |
| Total Unusual Items | $17,652,000 | $0 | $0 | - |
| Total Unusual Items Excluding Goodwill | $17,652,000 | $0 | $0 | - |
| Reconciled Depreciation | $1,409,000 | $1,748,000 | $1,515,000 | $691,000 |
| EBITDA (Bullshit earnings) | $-79,898,000 | $-142,322,000 | $-124,620,000 | $-82,943,000 |
| EBIT | $-81,307,000 | $-144,070,000 | $-126,135,000 | $-83,634,000 |
| Diluted Average Shares | $52,228,068 | $36,105,671 | $34,106,923 | $29,271,777 |
| Basic Average Shares | $52,228,068 | $36,105,671 | $34,106,923 | $29,271,777 |
| Diluted NI Availto Com Stockholders | $-61,797,000 | $-138,426,000 | $-117,255,000 | $-81,828,000 |
| Impairment Of Capital Assets | $2,205,000 | $0 | $0 | - |
| Gain On Sale Of Security | $19,857,000 | - | - | - |
| Research And Development | $61,979,000 | $118,085,000 | $102,546,000 | $62,713,000 |
| Selling General And Administration | $19,328,000 | $25,985,000 | $23,589,000 | $20,921,000 |
| Other Gand A | $19,328,000 | $25,985,000 | $23,589,000 | $20,921,000 |
Fetched: 2026-06-17
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $29,552,000 | $51,573,000 | $169,237,000 | $108,539,000 |
| Total Assets | $58,572,000 | $79,938,000 | $199,927,000 | $129,307,000 |
| Total Non Current Assets | $522,000 | $11,606,000 | $20,746,000 | $11,488,000 |
| Other Non Current Assets | $369,000 | $988,000 | $5,873,000 | $3,496,000 |
| Current Assets | $58,050,000 | $68,332,000 | $179,181,000 | $117,819,000 |
| Other Current Assets | $2,238,000 | $10,053,000 | $2,315,000 | $4,770,000 |
| Cash Cash Equivalents And Short Term Investments | $55,812,000 | $58,279,000 | $176,866,000 | $113,049,000 |
| Cash And Cash Equivalents | $55,812,000 | $58,279,000 | $176,866,000 | $111,899,000 |
| Prepaid Assets | - | - | - | - |
| Debt | ||||
| Total Debt | $1,589,000 | $8,771,000 | $10,296,000 | $2,285,000 |
| Long Term Debt And Capital Lease Obligation | $128,000 | $6,692,000 | $7,830,000 | $1,667,000 |
| Current Debt And Capital Lease Obligation | $1,461,000 | $2,079,000 | $2,466,000 | $618,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $29,020,000 | $28,365,000 | $30,690,000 | $20,768,000 |
| Total Non Current Liabilities Net Minority Interest | $17,919,000 | $6,692,000 | $7,830,000 | $1,667,000 |
| Derivative Product Liabilities | $17,791,000 | $0 | - | - |
| Current Liabilities | $11,101,000 | $21,673,000 | $22,860,000 | $19,101,000 |
| Other Current Liabilities | $169,000 | $203,000 | $192,000 | $636,000 |
| Payables And Accrued Expenses | $9,471,000 | $19,391,000 | $20,202,000 | $17,847,000 |
| Payables | $3,233,000 | $12,932,000 | $6,851,000 | $6,826,000 |
| Accounts Payable | $3,233,000 | $12,932,000 | $6,851,000 | $6,826,000 |
| Equity | ||||
| Common Stock Equity | $29,552,000 | $51,573,000 | $169,237,000 | $108,539,000 |
| Total Equity Gross Minority Interest | $29,552,000 | $51,573,000 | $169,237,000 | $108,539,000 |
| Stockholders Equity | $29,552,000 | $51,573,000 | $169,237,000 | $108,539,000 |
| Retained Earnings | $-449,048,000 | $-387,251,000 | $-248,825,000 | $-131,570,000 |
| Gains Losses Not Affecting Retained Earnings | - | - | $0 | $-1,000 |
| Other Equity Adjustments | - | - | - | $-1,000 |
| Preferred Securities Outside Stock Equity | - | - | - | - |
| Other | ||||
| Ordinary Shares Number | $72,299,440 | $36,310,713 | $35,866,610 | $29,561,554 |
| Share Issued | $72,299,440 | $36,310,713 | $35,866,610 | $29,561,554 |
| Tangible Book Value | $29,552,000 | $51,573,000 | $169,237,000 | $108,539,000 |
| Invested Capital | $29,552,000 | $51,573,000 | $169,237,000 | $108,539,000 |
| Working Capital | $46,949,000 | $46,659,000 | $156,321,000 | $98,718,000 |
| Capital Lease Obligations | $1,589,000 | $8,771,000 | $10,296,000 | $2,285,000 |
| Total Capitalization | $29,552,000 | $51,573,000 | $169,237,000 | $108,539,000 |
| Additional Paid In Capital | $478,593,000 | $438,820,000 | $418,058,000 | $240,107,000 |
| Capital Stock | $7,000 | $4,000 | $4,000 | $3,000 |
| Common Stock | $7,000 | $4,000 | $4,000 | $3,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $128,000 | $6,692,000 | $7,830,000 | $1,667,000 |
| Current Capital Lease Obligation | $1,461,000 | $2,079,000 | $2,466,000 | $618,000 |
| Current Accrued Expenses | $6,238,000 | $6,459,000 | $13,351,000 | $11,021,000 |
| Net PPE | $153,000 | $10,618,000 | $14,873,000 | $7,992,000 |
| Accumulated Depreciation | $-1,009,000 | $-4,179,000 | $-2,431,000 | $-916,000 |
| Gross PPE | $1,162,000 | $14,797,000 | $17,304,000 | $8,908,000 |
| Leases | $482,000 | $3,439,000 | $3,195,000 | $801,000 |
| Other Properties | $102,000 | $10,780,000 | $13,566,000 | $4,482,000 |
| Machinery Furniture Equipment | $578,000 | $578,000 | $539,000 | $455,000 |
| Properties | $0 | $0 | $0 | $0 |
| Construction In Progress | - | $0 | $4,000 | $3,170,000 |
| Investments And Advances | - | - | $0 | $0 |
| Other Short Term Investments | - | - | $0 | $1,150,000 |
Fetched: 2026-06-17
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-70,371,000 | $-120,256,000 | $-99,962,000 | $-63,447,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-70,371,000 | $-119,894,000 | $-96,592,000 | $-62,417,000 |
| Cash Flow From Continuing Operating Activities | $-70,371,000 | $-119,894,000 | $-96,592,000 | $-62,417,000 |
| Operating Gains Losses | $-19,857,000 | - | - | - |
| Investing Activities | ||||
| Investing Cash Flow | $0 | $-362,000 | $-2,220,000 | $27,341,000 |
| Cash Flow From Continuing Investing Activities | $0 | $-362,000 | $-2,220,000 | $27,341,000 |
| Capital Expenditure | - | $-362,000 | $-3,370,000 | $-1,030,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $67,745,000 | $0 | $161,803,000 | $0 |
| Financing Cash Flow | $67,904,000 | $1,668,000 | $163,798,000 | $1,239,000 |
| Cash Flow From Continuing Financing Activities | $67,904,000 | $1,668,000 | $163,798,000 | $1,239,000 |
| Net Common Stock Issuance | $67,745,000 | $0 | $161,803,000 | $0 |
| Common Stock Issuance | $67,745,000 | $0 | $161,803,000 | $0 |
| Net Preferred Stock Issuance | - | - | - | $0 |
| Preferred Stock Issuance | - | - | - | $0 |
| Other | ||||
| End Cash Position | $56,181,000 | $58,648,000 | $177,236,000 | $112,250,000 |
| Beginning Cash Position | $58,648,000 | $177,236,000 | $112,250,000 | $146,087,000 |
| Changes In Cash | $-2,467,000 | $-118,588,000 | $64,986,000 | $-33,837,000 |
| Proceeds From Stock Option Exercised | $159,000 | $1,668,000 | $1,995,000 | $1,239,000 |
| Net Investment Purchase And Sale | $0 | $0 | $1,150,000 | $28,371,000 |
| Sale Of Investment | $0 | $0 | $1,150,000 | $28,371,000 |
| Net PPE Purchase And Sale | $0 | $-362,000 | $-3,370,000 | $-1,030,000 |
| Purchase Of PPE | $0 | $-362,000 | $-3,370,000 | $-1,030,000 |
| Change In Working Capital | $-3,698,000 | $-5,148,000 | $2,330,000 | $7,669,000 |
| Change In Other Current Liabilities | $-2,177,000 | $-1,501,000 | $-2,238,000 | $-565,000 |
| Change In Other Current Assets | $619,000 | $4,884,000 | $-2,358,000 | $-1,915,000 |
| Change In Payables And Accrued Expense | $-9,955,000 | $-793,000 | $4,448,000 | $11,874,000 |
| Change In Accrued Expense | $-255,000 | $-6,881,000 | $1,886,000 | $8,914,000 |
| Change In Payable | $-9,700,000 | $6,088,000 | $2,562,000 | $2,960,000 |
| Change In Account Payable | $-9,700,000 | $6,088,000 | $2,562,000 | $2,960,000 |
| Change In Prepaid Assets | $7,815,000 | $-7,738,000 | $2,478,000 | $-1,725,000 |
| Other Non Cash Items | $1,847,000 | $2,838,000 | $2,686,000 | $571,000 |
| Stock Based Compensation | $9,520,000 | $19,094,000 | $14,131,000 | $10,336,000 |
| Asset Impairment Charge | $2,205,000 | $0 | $0 | - |
| Amortization Of Securities | $0 | $0 | $1,000 | $144,000 |
| Depreciation Amortization Depletion | $1,409,000 | $1,748,000 | $1,515,000 | $691,000 |
| Depreciation And Amortization | $1,409,000 | $1,748,000 | $1,515,000 | $691,000 |
| Depreciation | $1,409,000 | $1,748,000 | $1,515,000 | $691,000 |
| Gain Loss On Investment Securities | $-19,857,000 | - | - | - |
| Net Income From Continuing Operations | $-61,797,000 | $-138,426,000 | $-117,255,000 | $-81,828,000 |
| Net Issuance Payments Of Debt | - | - | $0 | $0 |
| Net Long Term Debt Issuance | - | - | $0 | $0 |
| Purchase Of Investment | - | - | $0 | $0 |
Fetched: 2026-06-17